Medical device company Nevro Corp. (NYSE: NVRO), that specialises in chronic pain treatment, on Monday released new data showcasing the cost-effectiveness of its proprietary 10 kHz Therapy, a high-frequency spinal cord stimulation (SCS) therapy. The data, based on health care utilization (HCU) assessments, reveal substantial reductions in hospital resource usage associated with 10 kHz Therapy for treating Painful Diabetic Neuropathy (PDN) and nonsurgical refractory back pain.
In a study published in the Journal of Managed Care & Specialty Pharmacy, patients receiving 10 kHz Therapy for PDN demonstrated half the hospitalisation rate compared to conventional medical management (CMM), resulting in 51% lower healthcare costs per patient.
Another analysis, published in the Journal of Neurosurgery: Spine, assessed the cost-effectiveness of 10 kHz Therapy for nonsurgical refractory back pain patients, showing that it provides a higher quality of life at a lower average cost per patient compared to CMM therapy. Cost-effectiveness is predicted within 2.1 years.
A third study, published in Neuromodulation, examined the cost impact of 10 kHz Therapy for Chronic Refractory Low Back Pain patients. The analysis indicated a significant reduction in total healthcare costs, offsetting device acquisition expenses within 27 months.
Furthermore, data published in the Journal of Diabetes Science and Technology illustrated that 10 kHz Therapy substantially decreases healthcare utilization in PDN patients.
PDN is a progressive, chronic neuropathic pain condition affecting 20% of diabetes patients. In the US, approximately 140,000 to 200,000 PDN patients annually, refractory to conventional medical management, represent a market opportunity of USD3.5bn to USD5.0bn.
Headquartered in Redwood City, California, Nevro's 10 kHz Therapy has impacted over 100,000 patients worldwide. The company's comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza SCS system and support services for trunk and limb chronic pain and painful diabetic neuropathy treatment. Senza, Senza II, Senza Omnia, and HFX iQ are the only SCS systems delivering Nevro's proprietary 10 kHz Therapy. HFX Coach and HFX Cloud provide personalised patient support and enhanced practice management insights for physicians.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration